Voclosporin ( DrugBank: Voclosporin )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
49	全身性エリテマトーデス	1
222	一次性ネフローゼ症候群	1

49. 全身性エリテマトーデス

---

臨床試験数 : 993 /  薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05306873 (ClinicalTrials.gov)	October 28, 2022	11/3/2022	Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus	A Phase 2, Double-Blind, Placebo-Controlled Trial of Mycophenolate Mofetil Alone or With Voclosporin for Systemic Lupus: Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment (DIVERT) (ALE10)	Systemic Lupus Erythematosus	Drug: Mycophenolate Mofetil;Drug: Placebo for Mycophenolate Mofetil;Drug: Voclosporin;Drug: Placebo for Voclosporin	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Recruiting	18 Years	60 Years	All	120	Phase 2	United States

222. 一次性ネフローゼ症候群

---

臨床試験数 : 310 /  薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03598036 (ClinicalTrials.gov)	June 21, 2018	14/6/2018	Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis	An Open-Label Dose-Exploration Cohort Study Evaluating the Efficacy and Safety of Voclosporin in Achieving Complete or Partial Remission of Proteinuria in Subjects With Focal Segmental Glomerulosclerosis	Focal Segmental Glomerulosclerosis	Drug: Voclosporin	Aurinia Pharmaceuticals Inc.	NULL	Terminated	18 Years	75 Years	All	5	Phase 2	United States;Dominican Republic